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Abstract
Background: While bone marrow (BM) is a rich source of mesenchymal stem cells (MSCs), previous studies have shown that
MSCs derived from mouse BM (BMMSCs) were difficult to manipulate as compared to MSCs derived from other species. The
objective of this study was to find an alternative murine MSCs source that could provide sufficient MSCs.
Methodology/Principal Findings: In this study, we described a novel type of MSCs that migrates directly from the mouse
epiphysis in culture. Epiphysis-derived MSCs (EMSCs) could be extensively expanded in plastic adherent culture, and they
had a greater ability for clonogenic formation and cell proliferation than BMMSCs. Under specific induction conditions,
EMSCs demonstrated multipotency through their ability to differentiate into adipocytes, osteocytes and chondrocytes.
Immunophenotypic analysis demonstrated that EMSCs were positive for CD29, CD44, CD73, CD105, CD166, Sca-1 and SSEA-
4, while negative for CD11b, CD31, CD34 and CD45. Notably, EMSCs did not express major histocompatibility complex class I
(MHC I) or MHC II under our culture system. EMSCs also successfully suppressed the proliferation of splenocytes triggered by
concanavalin A (Con A) or allogeneic splenocytes, and decreased the expression of IL-1, IL-6 and TNF-a in Con A-stimulated
splenocytes suggesting their anti-inflammatory properties. Moreover, EMSCs enhanced fracture repair, ameliorated necrosis
in ischemic skin flap, and improved blood perfusion in hindlimb ischemia in the in vivo experiments.
Conclusions/Significances: These results indicate that EMSCs, a new type of MSCs established by our simple isolation
method, are a preferable alternative for mice MSCs due to their better growth and differentiation potentialities.
Citation: Cheng C-C, Lian W-S, Hsiao FS-H, Liu I-H, Lin S-P, et al. (2012) Isolation and Characterization of Novel Murine Epiphysis Derived Mesenchymal Stem
Cells. PLoS ONE 7(4): e36085. doi:10.1371/journal.pone.0036085
Editor: Giovanni Camussi, University of Torino, Italy
Received December 12, 2011; Accepted March 26, 2012; Published April 27, 2012
Copyright:  2012 Cheng et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from National Taiwan University (97,99R0066-41) and Council of Agriculture (99AS-1.2.3-ST-aM). The funders had
no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: scw01@ntu.edu.tw
Introduction
Friedenstein and colleagues first defined mesenchymal stem cells
(MSCs) in the 1970s as cells that are capable of self-renewal and
possess multipotency [1]. Over decades MSCs have been shown to
not only be able to differentiate into three mesodermal lineages,
including adipocytes, osteocytes and chondrocytes [2,3,4], but also
into cells types with non-mesenchymal lineages, such as hepato-
cytes [5,6], pancreatic-like cells [7,8,9] and neuron-like cells
[10,11]. Hence, MSCs have become an attractive cell source for
use in regenerative medicine. In addition, the low immunogenicity
of MSCs makes them suitable for use in transplantation
[12,13,14], and their immunomodulatory properties make them
suitable for use in the treatment of many immune disorders
[15,16,17].
MSCs were initially obtained from bone marrow [1,4], but they
can also be derived from other sources, such as skeletal muscle
[18], umbilical cord blood [19,20], dental pulp [21], adipose tissue
[22,23] and amniotic fluid [24,25]. MSCs have been successfully
isolated and expanded from human [4], rat [26], rabbit [27],
canine [26], pig [28] and mouse [29]. Mouse is the most widely
used species in laboratory research because they are easy to
manipulate and their genetic information is readily available.
However, murine is the most difficult species to establish MSCs
from BM [30]. Murine BM is composed of heterogeneous cell
populations that contain few MSCs (10
25–10
26 cells) [31]. In
addition, BMMSCs are located near the inner surface of the bone,
making it difficult to flush them out [32]. Another problem in
establishing mouse BMMSCs is contamination with large amount
of hematopoietic cells [33]. Therefore, it is necessary to expand
MSCs ex vivo. Such manipulation could cause cellular senescence
by the loss of proliferation, differentiation and therapeutic
potentials [34,35]. This prompted us to look for an alternative
source for MSCs with better ex vivo expansion capability.
Endochondral ossification occurs during the process of long
bone formation in foetal development. Primary ossification occurs
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e36085at the bone centre for forming marrow cavity, while secondary
ossification is formed in the bone epiphysis, followed by the
formation of uncalcified cartilage, perichondrium and epiphyseal
blood vessel penetration [36,37,38]. Hence, we hypothesized the
possibility of a biological niche for mesenchymal progenitors in the
epiphysis. In this study, we derived novel MSCs from murine
epiphysis without enzymatic digestion. We characterized the
morphology, proliferation and functional properties of EMSCs
and compared these results with those of BMMSCs under the
same cell culture conditions. We also evaluated the therapeutic
effects of EMSCs on bone fracture and two types of ischemia
mouse animal models. To our knowledge, this is a novel approach
for the isolation of MSCs from murine bone.
Results
Establishment of EMSCs
Because surface antigens specific to MSCs have not been
identified, MSCs are mainly isolated using their characteristic of
plastic adherence. We obtained BMMSCs using a BM flush-out
method and EMSCs using our newly developed method for
acquiring MSCs (Figure 1A). Epiphysis was dissected out and
directly cultured in culture dishes without enzymatic digestion.
After seven days of culturing, EMSCs can be observed as triangle,
spindle-shaped (Figure 1B), while BMMSCs had a flat, spindle-
shaped morphology (Figure 1C). Since both methods had the same
problem of hematopoietic cells contamination, we purified the
primary culture of EMSCs migrating from epiphysis and
BMMSCs from bone marrow by the transient lower-density
plastic adherence (tLDA) method [39] to avoid hematopoietic cells
contamination. In subsequent passages, EMSCs maintained their
characteristic spindle-shape (Figure 1D), whereas BMMSCs
changed their morphology and displayed enlarged and flattened
phenotypic appearances (Figure 1E).
Characterization of EMSCs
To verify the cells derived from the epiphysis are MSCs, a panel
of antibodies against stem cells markers was chosen to evaluate
whether the phenotypes of EMSCs are similar to MSCs. EMSCs
were positive for most positive BMMSCs markers, such as CD29,
CD44, CD73, CD105 (Figure 2A) and with stronger Sca-1 signal
than BMMSCs (Figure 2A, 2B), while negative for hematopoietic
cells markers, CD11b, CD45 and CD34, and for endothelial cell
marker, CD31 (Figure 2A) as BMMSCs (Figure 2B). In addition,
EMSCs were positive for markers, CD106, CD166 and SSEA-4
(Figure 2A), while BMMSCs were negative (Figure 2B).
MSCs have reportedly low immunogenicity, because MHC II is
not expressed. We found that EMSCs were also negative for MHC
II (Figure 2A). Interestingly, EMSCs were negative for MHC I
(Figure 2A), whereas BMMSCs were positive (Figure 2B). To test
whether the EMSCs are able to express MHC I, we treated
EMSCs with 10 ng and 200 ng IFN-c (Figure 3A, 3B,
respectively) and detected the MHC molecules expressions.
Although MHC class I and II molecules were not expressed by
EMSCs under our isolation method and culture conditions, their
expression could be induced by IFN-c treatment.
Furthermore, we monitored immunophenotype changes that
occurred during serial passages. Among the antibody panel used,
four surface markers gradually decreased with increased serial
passage, including CD73, CD166, SSEA-4 and Sca-1 (Figure 3C),
which became more similar to BMMSCs (Figure 2B) but the
MHC I expression was still negative even with additional passages
(data not shown).
EMSCs Have Better Proliferation Potential
We evaluated EMSCs proliferation potential using a colony-
forming assay. EMSCs formed 23.1762.92 CFUs, showing
significantly higher clonogenic ability than BMMSCs
(5.8361.60 CFUs) (Figure 4A). EMSCs also contained more
CFUs that grow into large colonies than BMMSCs (Figure 4B).
The population doubling time (PDT) assay was performed to
evaluate the proliferation ability of EMSCs. The curves of both
EMSCs at the third and the fifth passages were higher than
Figure 1. Establishment of EMSCs and BMMSCs. (A) Schematic
protocol for the establishment of cultures of EMSCs and BMMSCs. (B)
Phase-contrast micrograph of EMSCs in primary culture after seven
days. Arrow heads indicate triangle, spindle-shaped, fibroblast-like
EMSCs. Lymphohematopoietic cells are indicated by arrows. (C) Phase-
contrast micrograph of BMMSCs in primary culture after seven days.
Arrow heads indicate flat, fibroblast-like BMMSCs and arrows indicate
lymphohematopoietic cells. (D) Phase contrast micrograph of EMSCs at
the fifth passage showing that EMSCs maintained their shape during
propagating. (E) Phase contrast micrograph of BMMSCs upon the fifth
passage showing that BMMSCs became flatted with increasing
passages. All the scale bars represent 100 mm.
doi:10.1371/journal.pone.0036085.g001
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(27.9962.34 hours at the third passage and 29.5160.70 hours
at the fifth passage) were less than that for BMMSCs (46.6363.11
and 70.7865.18 hours) (Figure 4C). Hence, EMSCs showed
higher proliferation capability than BMMSCs. We further
investigated the propagating ability of EMSCs, and the data
showed that EMSCs could be significantly propagated until
passage nine in which the cell number was not significantly
increased in next passage (Figure 4D). In contrast, BMMSCs could
only be propagated until passage five (Figure 4D). Thus, EMSCs
can reach to a higher propagating passage than BMMSCs and
have higher proliferative potential.
Since telomere length and telomerase activity are in relation to
cell proliferation and aging, we further evaluated these properties
in EMSCs and BMMSCs, and according by both telomere length
and telomerase activity were greater in EMSCs than in BMMSCs
(Figure 4E, 4F). Hence, EMSCs derived by our protocol showed
higher proliferation potential.
Figure 2. Immunophenotypes of EMSCs and BMMSCs. (A) Flow cytometric analysis of markers related to stem cells, mesenchymal stem cells,
hematopoietic cells, endothelial cells and immune cells on EMSCs and (B) BMMSCs at the first passage. The dotted line indicates the respective
isotype control.
doi:10.1371/journal.pone.0036085.g002
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BMMSCs
Previous studies have demonstrated that MSCs are capable of
differentiation into osteocytes, adipocytes and chondrocytes.
Firstly, we investigated and compared the in vitro adipogenic
differentiation capability by culturing EMSCs and BMMSCs in
adipogenic induction medium and performing histochemical
staining with Oil Red O. EMSCs formed more intracellular lipid
droplets upon staining (Figure 5A-i, 5A-ii) compared to BMMSCs
(Figure 5A-iii, 5A-iv). Lipid droplets observed in EMSCs were also
larger and more apparent. Quantitative analysis of Oil Red O
staining showed that EMSCs had significantly better adipogenic
differentiation capability than BMMSCs (Figure 5B). Accordingly,
quantification of the adipogenic gene expression also showed that
EMSCs had stronger expression both in early adipogenesis marker
PPARc (Figure 5C) and late adipogenesis marker LPL (Figure 5D).
Furthermore, EMSCs maintained negative expression of MHC I
during adipogenesis (Figure 5E).
Secondly, after a seven-day culture period in osteogenic
induction medium, EMSCs formed calcium deposition and
mature nodules structures, which were stained with Alizarin red
S (ARS) (Figure 5F-i, 5F-ii). Compared to BMMSCs (Figure 5F-iii,
5F-iv), EMSCs formed relatively more nodules. Quantitative
results from ARS staining showed that EMSCs had better
osteogenic differentiation capability than BMMSCs (Figure 5G).
The qPCR data showed greater expression of early osteogenic
marker Runx2 (Figure 5H) and late osteogenic marker Colla1
(Figure 5I) in EMSCs than in BMMSCs. Furthermore, EMSCs
maintained negative expression of MHC I during osteogenesis
(Figure 5J).
Finally, the chondrogenic differentiation capability of EMSCs
and BMMSCs were analyzed using a pelleted micromass culture
system. After 21 days of chondrogenic induction culture, EMSCs
differentiated into chondrocytes. The formation of chondrocytes
was confirmed with toluidine blue staining, shown as a purple-
colour stained matrix (Figure 5K-i). EMSCs showed more
toluidine blue positive staining, whereas BMMSCs were only
faintly stained (Figure 5K-ii) suggesting that EMSCs were more
efficient in chondrogenesis.
Although both EMSCs and BMMSCs were able to differentiate
into mesodermal cell lineages including adipocytes, osteocytes and
chondrocytes, EMSCs showed higher potential to differentiate into
these lineages.
Figure 3. Surface markers analysis of EMSCs after IFN-c treatment and during increased serial passages. (A) MHC I and MHC II
expression profiles for EMSCs (passage five) were analysed under 10 ng or (B) 100 ng IFN-c treatment. EMSCs were positive for MHC I and MHC II after
IFN-c treatment. (C) EMSCs surface antigen profiles were detected via flow cytometric analysis during increasing passages. The markers of CD73,
CD166, SSEA-4 and Sca-1 were decreased with propagating. Respective isotype control is indicated by the dotted line.
doi:10.1371/journal.pone.0036085.g003
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Senescence can be identified not only by morphological
evaluation but also by the expression of senescence-associated b-
galactosidase (SA-b-gal). Blue SA-b-gal-positive cells could be
found in both EMSCs (Figure 6A) and BMMSCs cultures
(Figure 6B). Quantified data showed that there were more SA-b-
gal-positive cells in BMMSCs than in EMSCs (Figure 6C).
Figure 4. Cell proliferation profiles of EMSCs and BMMSCs. (A) Colony-forming activity of EMSCs and BMMSCs at the first passage. EMSCs
formed 23.1762.92 CFUs whereas BMMSCs formed 5.8361.60 CFUs (n=6). (B) CFUs size distribution for EMSCs and BMMSCs. EMSCs formed more
and larger CFUs than BMMSCs. ** represents P,0.01 (n=6). (C) PDTs for EMSCs were compared to BMMSCs at the third (P3) and the fifth (P5)
passages. The curves of EMSCs are higher than the ones of BMMSCs (n=3). * represents P,0.05, ** represents P,0.01, which was compared at the
third passage. # represents P,0.05, ## represents P,0.01, which was compared at the fifth passage. (D) Propagating abilities of EMSCs and
BMMSCs. Cells were propagated for 2 days at each passage and cell numbers were calculated. EMSCs could be propagated for more passages that
cells still retained proliferation ability than BMMSCs (n=5). * represents P,0.05, ** represents P,0.01, as compared to previous passage. (E) Telomere
length and (F) telomerase activity of EMSCs and BMMSCs (at the first passage) were detected and compared. EMSCs expressed significantly longer
telomere length and higher telomerase activity than BMMSCs (n=3). * represents P,0.05, ** represents P,0.01. Data are presented as mean 6 s.d.
and analyzed with Student’s t-test.
doi:10.1371/journal.pone.0036085.g004
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PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e36085Figure 5. Differentiation potential of EMSCs and BMMSCs. (A) Adipogenic differentiation of EMSCs and BMMSCs at the fifth passage.
Adipogenic capability was characterized by Oil Red O staining after seven days induction. EMSCs showed larger and more lipid drops than BMMSCs.
(B) Oil Red O staining of EMSCs and BMMSCs were quantified for comparison (n=3). (C, D) Expression level of adipogenic related genes were assessed
by qPCR. EMSCs showed higher adipogenic gene expression level after seven days induction (n=3). (E) MHC I expression profile of EMSCs was
analysed by flow cytometry after seven days adipogenic induction. After adipogenesis, EMSCs were still negative for MHC I expression. (F) Osteogenic
differentiation of EMSCs and BMMSCs at the fifth passage. Osteogenic capability was characterized by ARS staining after seven days induction. EMSCs
showed higher calcium deposition than BMMSCs. (G) Quantitative results of ARS were performed to compare the osteogenic capacity of EMSCs and
BMMSCs (n=3). (H, I) Expression level of osteogenic related genes were assessed by qPCR. EMSCs showed higher osteogenic gene expression level
after seven days induction (n=3). (J) MHC I expression profile of EMSCs was analysed by flow cytometry after seven days osteogenic induction. After
osteogenesis, EMSCs were still negative for MHC I expression. (K) Chondrogenic differentiation of EMSCs and BMMSCs at the fifth passage.
Chondrogenic capability was evaluated by histological section of micromass pellet cultures after 21 days induction. Glycosaminoglycan content of
the pellet was characterized by toluidine blue staining. EMSCs showed deeper purple stained matrix than BMMSCs. All the scale bars represent
100 mm. ** represents P,0.01. Data are presented as mean 6 s.d. and analyzed with Student’s t-test.
doi:10.1371/journal.pone.0036085.g005
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kinase inhibitors) and senescence markers, p16 and p21. The
transcript expression level of both p16 and p21 (Figure 6D, 6E)
were lower in EMSCs than in BMMSCs.
EMSCs are Immunosuppressive and Anti-inflammatory
MSCs show low immunogenicity and exhibit the ability to
suppress T-cell proliferation stimulated by either non-specific
lymphocyte mitogens or mix lymphocyte reaction. We speculated
that EMSCs have similar features. EMSCs co-cultured with
autologous C57BL/6 splenocytes in the presence of Con A
significantly inhibited Con A-induced splenocyte proliferation in a
dose-dependent manner (Figure 7A). For EMSCs co-cultured with
allologous BALB/c splenocytes stimulated by Con A, the same
effects could be observed (Figure 7B). In addition, EMSCs also
repressed the allogeneic-induced splenocyte proliferation when co-
cultured with allogeneic-stimulated splenocytes. Similarly, EMSCs
exhibited dose-dependent suppression with allogeneic T-cell
response (Figure 7C). These results indicated that EMSCs were
able to suppress splenocyte proliferation in vitro and suggested
EMSCs’ role in immunosuppression.
To determine if anti-inflammatory actions of EMSCs could be
induced through a paracrine effect, EMSCs and splenocytes were
separated using the trans-well culture system, and IL-1, IL-6 and
TNF-a of splenocytes were quantified. We found that IL-1, IL-6
and TNF-a were enhanced when splenocytes were stimulated by
Con A and the surge of these pro-inflammatory signals could be
repressed with the presence of EMSCs (Figure 7D–F). Hence,
EMSCs are immunosuppressive via suppressing T-cell prolifera-
tion and inhibiting the release of pro-inflammatory signals.
Therapeutic Potentials of EMSCs
EMSCs showed greater potentials of proliferation and differen-
tiation than BMMSCs, and also demonstrated paracrine anti-
inflammation ability by which derived various therapeutic effects
of MSCs [40,41]. To further confirm the potential of clinical
application of EMSCs, we first investigated the osteogenesis
potential of EMSCs using bone fracture model. EMSCs were
seeded on a collagen-based gelatin sponge (SPONGOSTAN) and
implanted into the fracture site. 14 days after surgery, osteocalci-
fication of the injured sites was evaluated by X-ray image, and
significantly higher bone density was observed in the EMSCs
treated group indicating that EMSCs can improve bone repair
response (Figure 8A, 8B). Histological examination of fracture sites
revealed that newly formed bone tissue and capillaries were
formed in the EMSCs implanted group while the control group
showed the presence of disorganized tissue accompanied with
more leukocytes infiltration (Figure 8C).
Recent studies showed MSCs could enhance angiogenesis and
that play a pivotal role in repairing ischemic tissue damage and
wound healing [42,43]. Therefore, we used mouse dorsal skin flap
to investigate the potential therapeutic effects of EMSCs in
ischemic chronic wound. In consistent with the results of other
sources of MSCs [44], EMSCs improved wound healing at
incisions (Figure 9A) and significantly reduced necrotic area
(6.9561.6%) as compared with the control group (29.963.94%)
(Figure 9B). Skin thickness in the EMSCs injected group was
decreased and the mucinous layer was enriched below the
platysma muscle when compared to the control group
(Figure 9C). More severe hemorrhages and erythrocyte extrava-
sations in the dermis could be observed in the control group than
in the EMSCs injected group (Figure 9D). Immunostaining of von
Willebrand factor (vWF) indicated a significantly increased
capillary density in the EMSCs injected group (Figure 9E, 9F),
and suggested that EMSCs have beneficial effects on chronic
ischemic wound healing probably by promoting angiogenesis.
A mouse hindlimb ischemia was also used to further confirm the
effect of EMSCs on angiogenesis in vivo. Seven days after the onset
of ischemia, laser Doppler perfusion imaging showed significant
recovery of perfusion in the EMSCs injected group (0.7160.12,
relative to the non-ischemic limb) as compared to the control
group (0.2160.09) (Figure 10A, 10B). H&E staining showed
Figure 6. Analysis of cellular aging related markers of EMSCs and BMMSCs. (A) Determination of senescence marker, SA-b-gal, upon the
fifth passage of EMSCs and (B) BMMSCs. SA-b-gal positive cells were showed as blue color and indicated by arrow heads. (C) The number of SA-b-gal
positive cells was calculated from EMSCs or BMMSCs cultures. EMSCs showed lower SA-b-gal positive cells than BMMSCs (n=4). (D) mRNA levels of
cyclin-dependent kinase inhibitors p16 and (E) p21 were evaluated by qPCR. Both p16 and p21 expression levels were lower in EMSCs than BMMSCs
(n=3). All the scale bars represent 100 mm. ** represents P,0.01. Data are presented as mean 6 s.d. and analyzed with Student’s t-test.
doi:10.1371/journal.pone.0036085.g006
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PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e36085Figure 7. Immunomodulatory properties of EMSCs. (A) Responding splenocytes from C57BL/6 or (B) BALB/c mice were stimulated with Con A
in the presence or absence of graded numbers of C57BL/6 EMSCs. The results are shown as percentage of cell proliferation in comparison with
control cell proliferation. Splenocytes proliferation was inhibited by culture with EMSCs (at the fifth passage) in a dose dependent manner (n=3). (C)
Responding splenocytes from C57BL/6 mice were cultured with an equal number of mitomycin C-treated BALB/c splenocytes and with or without
graded number of C57BL/6 EMSCs (n=3). Allo indicates allogeneic splenocytes culture. EMSCs inhibited the splenocyte proliferation stimulated by
allogeneic cells in a dose dependent manner. (D–F) Analysis of inflammatory cytokine production of splenocyte stimulated by Con A. Inflammatory
cytokines expression level of splenocytes were decreased when co-cultured with EMSCs (at the fifth passage) (n=3). * represents P,0.05,
**represents P,0.01. Data are presented as mean 6 s.d. and analyzed with Student’s t-test.
doi:10.1371/journal.pone.0036085.g007
Figure 8. Repair of bone fracture in mice after transplantation of EMSCs. (A) Fracture healing was assessed by X-ray after 14 days with or
without EMSCs (at the fifth passage) transplantation. Arrowheads indicate the site of fracture. (B) The bone density of fracture site (dotted box in
Figure 8A) was quantified (n=4). EMSCs transplantation significantly improved osteocalcification as compared to the control group. (C) The
morphology of fracture sites were examined by H&E staining. Tissue disorganization was showed in the control group while the EMSCs transplanted
group newly formed bone tissue (arrow) and capillaries (arrowhead). * represents P,0.05. Scale bars represent 100 mm. Data are presented as mean
6 s.d. and analyzed with Student’s t-test. Control: SPONGOSTAN carried with complete medium-transplantation group; EMSC: SPONGOSTAN carried
with EMSCs-transplantation group.
doi:10.1371/journal.pone.0036085.g008
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severe fibrosis in the ischemic region in the control group. On the
other hand, significantly reduced muscle degeneration and
minimal fibrosis were observed in the EMSCs treated group
(Figure 10C–10E). In consistent with the results from skin flap
model, immunostaining of vWF of ischemic muscle indicated an
increase in capillary density in the EMSCs injected group
(Figure 10F, 10G), and supported that EMSCs could promote
angiogenesis to improve in blood perfusion and muscle recovery in
ischemic hindlimbs.
Discussion
MSCs can serve as progenitors for bone, cartilage, adipose,
muscle and other tissues [45,46,47]. Despite the use of BMMSCs
as a common adult stem cell source, murine BM cells are more
difficult to isolate and culture than those of other species due to
low frequency and mixed cell contamination [48,49,50]. There-
fore the use of BMMSCs requires ex vivo cell expansion, and
usually results in more senescent cells. In addition to bone marrow,
researchers also tried to isolate MSCs from compact bone [51] or
trabecular bone [52,53] to overcome this limitation. The purpose
of this study was to find alternative murine MSCs sources that
provide sufficient MSCs in earlier passages. In this study, we
demonstrated that the epiphysis serves as an easy-access and rich
stem cell reservoir, resolving difficulties that arise from isolating
and expanding murine BMMSCs. To verify MSCs establishment,
EMSCs were analysed for general MSCs features and their key
capabilities were compared with those of BMMSCs.
The minimum criteria for defining MSCs includes three
parameters: clonogenic capabilities, specific surface antigens
identification and differentiation potentials [54]. Experimental
results revealed that EMSCs exhibited significantly stronger
colony- forming ability, not only in numbers but also in size,
when compared with BMMSCs. In addition, proliferation
capability was determined by PDT assay. We found that
BMMSCs growth decreased after few passages, whereas EMSCs
continued to grow rapidly. Hence, EMSCs might have an
advantage over BMMSCs in providing a large quantity of cells
in a short culture period.
We demonstrated through differentiation studies that EMSCs
have the potentials to differentiate into adipogenic, osteogenic and
chondrogenic cell lineages. EMSCs showed significantly better
differentiation capabilities than BMMSCs, especially in adipogen-
esis and chondrogenesis. In adipogenesis, EMSCs formed lipid
droplets more readily, and the number and size of lipid droplets in
EMSCs were more than in BMMSCs. Accordingly, EMSCs
expressed higher level of early (PPARc) and late (LPL)
adipogenesis markers than BMMSCs. In chondrogenesis, EMSCs
showed deeper coloured and larger mast cell accumulation on
toluidine blue staining. These results suggest that EMSCs exhibit
higher differentiation potentials than BMMSCs.
We examined the expression of EMSCs markers and found that
some differed from those of BMMSCs. The data confirmed that
EMSCs cultured in our system gave rise to a population of cells
with MSCs characteristics. In consistent with general MSCs
profiles, EMSCs were positive for CD29, CD44 and CD73, and
negative for CD11b, CD45 and CD31, suggesting that the
established EMSCs were not from hematopoietic and endothelial
lineages. EMSCs exhibited higher and more homogeneous Sca-1
expression might be related to their high proliferation capabilities
[55,56]. In accordance of previous studies, CD105 and CD166
were demonstrated to relate to chondrogenic potential [57,58] and
our data also indicated that EMSCs, with CD166 positive, were
superior in chondrogenic potential. Notably, EMSCs were
negative for MHC I expression under our culture condition,
Figure 9. Prevention of skin flap necrosis in mice by EMSCs injection. (A) Ischemic flap showed necrosis in the control mice and near
complete healing in the EMSCs (at the fifth passage) injected mice after 6 days of surgery. (B) Percentage of necrosis was quantified by planimetry.
Percentage of necrotic area is significantly larger in the control group than in the EMSCs injected group (n=4). (C) The skin structure was evaluated
by H&E staining. Skin thickness is decreased and mucinous layer is preserved in the EMSCs injected group as compared to the control group. (D) In
higher magnification, extra vascular erythrocytes and hemorrhage (arrowhead) can be observed in the control group. (E) Immunostaining of von
Willebrand factor (vWF) of skin flap, and (F) its quantification showed significantly more vWF expressed cells (arrowhead) in the EMSCs injected group
than the control group. **represents P,0.01. Scale bars represent 100 mm. Data are presented as mean 6 s.d. and analyzed with Student’s t-test. PM:
platysma muscle; ML: mucinous layer; Control: complete medium injection-group; EMSC: EMSCs-injection group.
doi:10.1371/journal.pone.0036085.g009
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cytokine known to enhance the MHC molecules expression,
EMSCs were found to be positive for MHC I, implying that MHC
I molecules exist in the cytoplasm, but not on the cell surface.
Following changes in phenotype that occured over several
passages revealed that CD73, CD166, SSEA-4 and Sca-1
decreased with increased propagation, and grew in similarity to
BMMSCs while the MHC I expression was still negative for
EMSCs. In conclusion, our established EMSCs can be classified as
mesenchymal stem cells and were distinct from BMMSCs.
In principle, cellular aging can be accelerated with increased
propagating and can affect amplified differentiation potential
[59,60]. Our results showed that cultured EMSCs showed less SA-
b-gal positive cells than BMMSCs over several passages. Cyclin-
dependent kinase markers, p16 and p21, were important for
terminal growth arrest, and EMSCs showed lower p16 and p21
expression than BMMSCs regardless of primary or longer
passages.
Due to the potentials of multilineage differentiation and low
immunogenicity, MSCs draw attention for the use in regenerative
medicine. Recent researches also demonstrated that some
therapeutic effects of MSCs may derive from their paracrine
effects [61,62]. In our study, EMSCs not only showed great
proliferation and differentiation potentials but also demonstrated
immunosuppressive and anti-inflammation capacities through a
paracrine effect. Thus, it is reasonable to expect that EMSCs are
at least as potential as other MSCs for cell therapy. We evaluated
the therapeutic effects of EMSCs in three animal models,
including bone fracture, skin flap and hindlimb ischemia models.
Our study showed that transplanted EMSCs accelerated the
fracture healing process and enhanced osteocalcification indicating
that EMSCs can promote fracture repair. It has been shown that
MSCs contribute to angiogenesis directly by participating in new
vessel formation, or indirectly by secreting angiogenic factors
[63,64,65]. Therefore, we used dorsal skin flap model, in which an
oxygen tension gradient occurs in the ischemic tissue [66], to
investigate the effects of EMSCs on the neovascularization in vivo.
Transplanted EMSCs obviously reduced necrosis and almost fully
protected the edge of the flap. In addition, EMSCs effectively
preserved skin structures including the mucinous layer which is
important for skin water content and tissue structural integrity
[67]. In hindlimb ischemia model, EMSCs improved blood
perfusion and reduced muscle degeneration and tissue fibrosis.
Moreover, EMSCs treatment significantly increased vWF positive
capillary cells in both skin flap and hindlimb ischemia models,
suggesting that EMSCs enhance neovascularization and might
play a beneficial role in ischemic/hypoxia environment.
Collectively, EMSCs were characterized as MSCs due to their
capacities for differentiation into multiple lineages and cell surface
marker expression profiles, while EMSCs were found to have
greater abilities to proliferate and differentiate than BMMSCs.
Our data demonstrates that EMSCs provide an efficient and
reproducible method for obtaining MSCs with high proliferating
potential, and hence EMSCs can be used as an alternative to
MSCs for cell therapy. We provide a novel and reliable method for
preparing an improved population of murine MSCs.
Figure 10. Transplanted EMSCs improved blood perfusion in ischemic limb. (A) Foot perfusion was evaluated by laser Doppler blood
perfusion analysis at day 7 post ischemia. In color-coded images, red represents normal perfusion, while dark blue represents low or absent perfusion.
(B) Quantification of the foot perfusion showed that EMSCs (at the fifth passage) transplantation significantly improved blood perfusion (n=3). (C)
H&E staining showed massive muscle degeneration in ischemic regions in the control group compared to the markedly reduced muscle
degeneration in the EMSCs group. (D) Masson’s Trichrome staining and (E) its quantification showed significantly larger fibrotic area in the control
group than the EMSCs injected group. (F) Immunostaining of von Willebrand factor (vWF) of ischemic limb muscle and (G) its quantification showed
significantly more vWF expressed cells (arrowhead) in the EMSCs injected group than the control group. Scale bars represent 100 mm. **represents
P,0.01. Data are presented as mean 6 s.d. and analyzed with Student’s t-test. Isch: ischemic limb; NI: non-ischemic limb; Control: complete medium
injection-group; EMSC: EMSCs-injection group.
doi:10.1371/journal.pone.0036085.g010
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Animals and Ethics Statement
C57BL/6 and BALB/c mice of 6–8 weeks were purchased from
the Laboratory Animal Center of Medical College in National
Taiwan University (Taipei, Taiwan). Mice were kept under
standard conditions, and all experimental procedures were
approved by the Institutional Animal Care and Use Committee
(IACUC) of National Taiwan University (approval number 96-
EL-22-NTU).
Isolation and Culture of EMSCs
C57BL/6 mice were sacrificed by cervical dislocation. The
femurs and tibias were isolated and the adherent soft tissues on
femurs and tibias were removed thoroughly. The epiphyses were
then removed by a shears and transferred to 22.1 cm
2 culture dish
(TPP, Trasadingen, Switzerland) and cultured in complete
medium composed of MEM alpha (Sigma-Aldrich, St. Louis,
MO) supplemented with 20% fetal bovine serum (FBS; ECS
tested; Hyclone, Logan, UT), 2 mM L-glutamine (Invitrogen,
Carlsbad, CA), 100 U/ml penicillin, and 100 mg/ml streptomycin
(Invitrogen). The cells were incubated in a humidified atmosphere
containing 95% air and 5% CO2 at 37uC. The non-adherent cells
were removed by changing the medium every 3 days. After 11
days, the primary culture reached approximately 70% confluence,
and the cells were detached by 0.25% trypsin/0.1 mM ethylene-
diaminetetraacetic acid (trypsin/EDTA; Invitrogen) for 1 min at
37uC. After that, the reaction was stopped by adding complete
medium. The cells that cannot be lifted within 1 min were
discarded. The detached cells were centrifuged at 400 g for 5 min
and resuspended in the complete medium and were ready for the
transient lower-density plastic adherence (tLDA) purification as
described below.
Isolation and Culture of BMMSCs
BMMSCs were obtained as previously described [39,68]. In
brief, the femurs and tibias were isolated from cervical dislocated
C57BL/6 mice and the adherent soft tissues were cleaned
thoroughly. Then the epiphyses were removed by a rongeur.
The marrow cells were harvested from diaphysis by inserting a
syringe needle (23-gauge and 26-gauge for femurs and tibias,
respectively) and flushing with complete medium consisting of
MEM alpha (Sigma-Aldrich) supplemented with 20% FBS
(Hyclone), 2 mM L-glutamine (Invitrogen), 100 U/ml penicillin,
and 100 mg/ml streptomycin (Invitrogen). We plated the cells onto
60 cm
2 culture dishes (TPP) at a density of 2610
5 cells/cm
2. The
cells were incubated in a humidified atmosphere containing 95%
air and 5% CO2 at 37uC. The non-adherent cells were removed
by changing medium every 3 days. When these primary cultures
reached 70% confluence, the cells were lifted by incubating with
0.25% trypsin/EDTA (Invitrogen) for 1 min at 37uC. These cells
were ready for tLDA purification as described below.
tLDA Approach
The tLDA approach has been described previously [39]. Briefly,
the lifted cells from the primary culture were passed through a
40 mm mesh (BD Biosciences, San Jose, CA) and then the filtered
single cells were replated onto 60 cm
2 culture dishes at a density of
1.25610
4 cells/cm
2. These cells were allowed to adhere for 2–3 h
at 37uC in a humidified atmosphere containing 95% air and 5%
CO2. Afterwards, the cells were lifted by incubating with 0.025%
trypsin/EDTA (Invitrogen) for 5 min at 37uC and were seeded at
a density of 5610
4 cells/cm
2 for subsequent analysis.
Population Doubling Time (PDT)
The mean PDT was calculated according to the equation:
TD=tplog2/(logNt2logNo), where Nt is the number of cells
harvested, No is the number of cells inoculated, and t is the time of
the culture (in hour). The trypan blue exclusion test was used to
count the cells with the hemocytometer [69].
Colony Formation Assay
For determination of colony forming units (CFUs), cells were
plated at a density of 150 cells/9.01 cm
2 culture dish (TPP). After
incubation for 9 days, the colonies formed were fixed by methanol
(Sigma-Aldrich) and stained with Geimsa solution (Sigma-Aldrich).
A cluster of at least 20 cells was defined as a CFU. CFU sizes and
CFU number were enumerated by a light microscope. To
determine the relationship between CFU size and cell number,
CFU was categorized depending on cell number per CFU: 20–50
cells/CFU, 51–100 cells/CFU, 101–150 cells/CFU and .151
cells/CFU.
In Vitro Differentiation
To induce adipogenic differentiation, cells were cultured to near
confluence and cultured in adipogenic induction medium
consisting of MEM alpha (Sigma-Aldrich) supplemented with
10% FBS (Hyclone), 10 mg/ml insulin (Sigma-Aldrich), 1 mM
dexamethasone (Sigma-Aldrich), 0.5 mM isobutyl-methylxanthine
(Sigma-Aldrich), and 100 mM indomethacin (Sigma-Aldrich) for 7
days. The induction medium was changed every 3 days [29]. At
the end of the differentiation period, cells were fixed with 10%
formalin for 10 min and lipid droplets were stained by Oil Red O
(Sigma-Aldrich) staining. To quantify the Oil Red O staining
results, we extracted the Oil Red O from lipid droplets by DMSO
(Sigma-Aldrich) and measured the absorbance by SpectraMax 190
ELISA plate reader (Molecular Devices, Sunnyvale, CA) at
550 nm.
To induce osteogenic differentiation, the confluent cells were
incubated in osteogenic induction medium consisting of MEM
alpha (Sigma-Aldrich) supplemented with 10% FBS (Hyclone),
0.1 mM dexamethasone (Sigma-Aldrich), 10 mM b-glycerolpho-
sphate (Sigma-Aldrich) and 50 mM ascorbic acid (Sigma-Aldrich)
for 7 days [29]. The induction medium was changed every 3 days.
The bone matrix mineralization was evaluated by Alizarin red S
(ARS; Sigma-Aldrich) staining. The ARS was extracted by adding
10% cetylpyridinium chloride (Sigma) in 8 mM Na2HPO4
(Merck, Darmstadt, Germany) and 1.5 mM KH2PO4 (Merck)
and the absorbance was measured by SpectraMax 190 ELISA
plate reader (Molecular Devices) at 550 nm.
To induce chondrogenic differentiation, a pellet culture system
was used to differentiate. Chondrogenic induction medium
consisted of MEM alpha supplemented with 1% FBS (Hyclone),
6.25 mg/ml insulin (Sigma-Aldrich), 50 mM ascorbic acid (Sigma-
Aldrich), and 10 ng/ml TGF-b1 (R&D Systems, Minneapolis,
MN). The induction medium was changed twice per week. The
production of proteoglycan was characterized by toluidine blue
(Sigma-Aldrich) staining [70].
Flow Cytometric Analysis
Cells were stained with fluorescent isothiocyanate (FITC) or PE-
conjugate monoclonal antibodies (Table 1) for 30 min at 4uCi n
dark according to the product instructions. Ten thousand events
were acquired on a FACSCalibur (BD Biosciences, Franklin
Lakes, NJ), and analyzed by FCS Express software (Version 4.0;
Denovo software, Los Angeles, CA). All experiments included
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(eBioscience, San Diego, CA).
Quantitative Real Time Reverse Transcription-Polymerase
Chain Reaction (qPCR)
Total cellular RNA was extracted using TRIzol reagent
(Invitrogen) and then treated with RNase free DNase Set
(Promega, Madison, MI) according to manufacturer’s instructions.
Reverse transcription reactions were performed with 5 mg total
RNA using the SuperScript First-Strand Synthesis System
(Invitrogen), according to the manufacturer’s instructions. Real-
time PCR (ABI PRISM 7000; Applied Biosystems; Foster City,
CA) was performed with 1 mL of the single-stranded cDNA sample
with SYBR Green PCR master mix (Applied Biosystems). The
sequences of primers used were as follows: forward 59-
CATGGCCTTCCGTGTTCCTA-39, reverse 59-GCGGCACG-
TCAGATCCA-39 for Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH); forward 59-ACATAAAGTCCTTCCCGCTGACCA-
39, reverse 59-AAATTCGGATGGCCACCTCTTTGC-39 for
peroxisome proliferator activated receptor gamma (PPARc); forward 59-
ACGAGCGCTCCATTCATCTCTTCA-39, reverse 59-TCT-
TGCTGCTTCTCTTGGCTCTGA-39 for lipoprotein lipase (LPL);
forward 59-GCTTTCATTAGGCAGGGCCAACAA-39, reverse
59- AGGGCTGGATCTCAAACTCACACA-39 for runt related
transcription factor 2 (Runx2); forward 59-TTCTCCTGGCAAA-
GACGGACTCAA-39, reverse 59- AGGAAGCTGAAGTCA-
TAACCGCCA-39 for collagen, type I, alpha 1 (Col1a1); forward 59-
GAACTCTTTCGGTCGTACCC-39, reverse 59-CGAATCTG-
CACCGTAGTTGA-39 for p16; forward 59- CCAGGCCAA-
GATGGTGTCTT-39, reverse 59-TGAGAAAGGATCAGC-
CATTGC-39 for p21. Annealing temperature was 60uC. Each
amplification reaction was checked to confirm the absence of
nonspecific PCR product by melting curve analysis. The relative
gene expression level was calculated and presented with the
2
2DDCt method. GAPDH was used as a reference gene to
normalize specific gene expression in each sample.
Quantification of Telomere Length
Average telomere length (ATL) was measured by real-time PCR
from total genomic mouse DNA as previous study [71]. In brief,
total genomic DNA was extracted using Dneasy Blood and Tissue
Kit (Qiagen, Hilden, Germany) according to manufacturer’s
instructions. 20 ng samples of each DNA were performed by real-
time PCR (ABI PRISM 7000; Applied Biosystems) with SYBR
Green PCR master mix (Applied Biosystems). The average
telomere length ratio was determined by the level of telomeric
DNA normalized to the quantity of a single copy gene, the acidic
ribosomal phosphoprotein PO (36B4). Forward and reverse telomeric
primers were 59-CGGTTTGTTTGGGTTTGGGTTTGGGTT-
TGGGTTTGGGTT-39 and 59-GGCTTGCCTTACCCTTA-
CCCTTACCCTTACCCTTACCCT-39 respectively. Forward
and reverse primers of 36B4 gene were 59-ACTGGTCTAG-
GACCCGAGAAG-39 and 59-TCAATGGTGCCTCTGGA-
GATT -39, respectively.
Telomerase Activity
Telomerase activity was performed in triplicates with the
TRAPezeH XL Telomerase Detection kit (Millipore, Billerica,
MA) as the manufacturer’s instructions. Briefly, cells were lysed by
CHAPS lysis buffer and incubated on ice for 30 min. Then, cells
were centrifuged at 12,000 g at 4uC, and the supernatant was
assayed for telomerase. For PCR amplification, each reaction
volume is 50 ml, containing 10 ml of the 56 TRAPezeH XL
Reaction Mix, 0.4 ml of Tag Polymerase (5 U/ml; Invitrogen),
37.6 ml of ddH2O, and 2 ml of the sample extracted. In a
themocycler (ABI 2700; Applied Biosystems), performed a 4-step
PCR at 94uC for 30 s, 59uC for 30 s, 72uC for 1 min for 36 cycles,
followed by a 72uC for 3 min extension step and then 55uC for
25 min, concluding with a 4uC incubation. The fluorescence of
each reaction was detected with a Fluoroskan Ascent FL
fluorescent plate reader (Labsystems; Farnborough, UK). The
telomerase activity was determined by calculating the log of the
relative ratio net fluorescence increase (D fluorescein absorbance/
D sulforhodamine absorbance) for each reaction described detail
in the manufacturer’s instructions
Table 1. List of Antibodies Used in Flow Cytometry Analysis.
Antibody Clone Ref. No. Conjugated Isotype Supplier
CD11b M1/70 12-0112 PE Rat IgG2b eBioscience
CD29 HMb1-1 12-0291 PE Armenian Hamster IgG eBioscience
CD31 390 12-0311 PE Rat IgG2a eBioscience
CD34 RAM34 560238 FITC RatIgG2a BD Pharmingen
CD44 IM7 12-0441 PE Rat IgG2b eBioscience
CD45 30-F11 12-0451 PE Rat IgG2b eBioscience
CD73 TY/11.8 12-0731 PE Rat IgG1 eBioscience
CD105 MJ7/18 12-1051 PE Rat IgG2a eBioscience
CD106 429 11-1061 FITC Rat IgG2a eBioscience
CD117 2B8 12-1171 PE Rat IgG2b eBioscience
CD166 eBioALC-48 12-1661 PE Rat IgG2a eBioscience
Sca-1 D7 12-5981 PE Rat IgG2a eBioscience
SSEA-4 MC-813-70 12-8843 PE Mouse IgG3 eBioscience
MHC class I 34-1-2S 12-5998 PE Mouse IgG2a eBioscience
MHC class II M5/114.15.2 12-5321 PE Rat IgG2b eBioscience
doi:10.1371/journal.pone.0036085.t001
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Cells were grown to 50% confluence and stained by senescence
cells histochemical staining kit (Sigma-Aldrich) as manual
described. Briefly, cells were fixed in fixation buffer, washed with
PBS and stained the cells by incubating in freshly prepared
staining mixture at 37uC without O2 overnight.
Mitogen Proliferation Assays and Allogeneic Mixed
Lymphocyte Reaction (MLR)
The splenocytes from C57BL/6 and BALB/c mice were
prepared using Ficoll-Paque density centrifugation (1.077 g/ml;
Amersham Pharmacia Biotech, NJ) followed by two washes in
RPMI 1640 (Invitrogen) supplemented with 50 mM 2-mercapto-
ethanol (Sigma-Aldrich), 10% FBS (Hyclone), 100 U/ml penicil-
lin, and 100 mg/ml streptomycin (Invitrogen). A graded number of
mitomycin C (Sigma-Aldrich)-treated EMSCs or BMMSCs were
seeded in triplicate in flat-bottom 96-well plates and maintained at
37uC for 6 h. In mitogen proliferation assays, splenocytes (2610
5
cells/well) from C57BL/6 or BALB/c mice treated with 5 mg/ml
Con A (Sigma-Aldrich) were cultured with or without EMSCs or
BMMSCs from C57BL/6 mice. In MLR, responding splenocytes
(2610
5 cells/well) from C57BL/6 mice and an equal number of
mitomycin C-treated allogeneic stimulating splenocytes from
BALB/c mice were added into the EMSCs or BMMSCs culture.
Proliferation assays were performed after 4 or 5 days using the
CellTiter 96 Aqueous Nonradioactive Cell Proliferation Assay kit
(Promega, Madison, WI), according to the manufacturer’s
instructions. The absorbance was measured by SpectraMax 190
ELISA plate reader (Molecular Devices) at 490 nm.
Transwell and Coculture Assay
EMSCs (2610
4 cells/ml) were cultured in an upper chamber of
the Transwell insert (Millipore) with or without splenocytes (2610
6
cells/ml) cultured in a lower chamber. The transwell membrane
was semipermeable with a pore size of 0.4 mm. After three days of
culture, splenocytes were collected for mRNA analysis.
Bone Fracture Model
Eight-week-old female C57BL/6 mice were subjected to a bone
fracture model as previously described [72,73]. Briefly, a closed
transverse fracture was performed in the midsection of the femur
by a motorized drill (2 mm in diameter) and fractured femurs were
reconnected by a pin (25-gauge needle). EMSCs (5610
5 cells/
mouse) were plated on 2 mm62 mm SPONGOSTAN (Johnson
& Johnson, New Jersey, USA) at 37uC for 2 h and then
transplanted by covering on the fracture site. Experimented mice
were examined by X-ray (SkyScan 1076; SkyScan, Belgium) 14
days post-transplantation and the bone density of the fracture site
was assessed using ImageJ software (NIH). Femurs were collected
for hematoxylin and eosin (H&E) staining.
Skin Flap Model
Eight-week-old female C57BL/6 mice underwent skin flap
surgery at their back as previously described [74,75]. In brief, a
peninsular-shaped flap (3 cm62 cm) was elevated on mouse dorsal
skin and two vascular pedicles from the lateral thoracic arteries
were sectioned. Following surgery, the flap was injected with
200 ml of EMSCs (5610
5 cells/mouse) or complete medium
intradermally using 29-guage needle. The injected solution was
separated at four sites near the vascular cutting sites. Mice were
photographed for six days after the surgery and then sacrificed to
collect flap tissues for H&E staining and immunostaining. The
necrotic area was quantified using the ImageJ software (NIH).
Hindlimb Ischemia Model
Eight-week-old female C57BL/6 mice were subjected to
surgical ligature at the proximal end of the left femoral artery as
previously described [76,77]. Seven days after surgery, 100 mlo f
EMSCs (2610
6 cells/mouse) or complete medium was injected
intramuscularly into 5 sites of the gracilis muscle in the medial
thigh immediately. Laser Doppler perfusion imaging (moorLDI2;
Moor Instruments Ltd., Devon, UK) was performed seven days
after the surgery and ischemic limb muscles were then harvested
for immunohistochemistry analysis. H&E staining and Masson’s
Trichrome (Sigma-Aldrich) staining were performed, and fibrosis
area was calculated with ImageJ software (NIH).
Immunohistochemical Staining
Samples were embedded in paraffin blocks. Tissue slides were
deparaffinized, treated with epitope retrieval buffer (Thermal
scientific, Inc., Odessa, TX) at 95uC for 25 min, and then
incubated with a primary antibody, rabbit anti-von Willebrand
factor (vWF; 1:400; Abcam, Cambridge, UK), at 4uC overnight.
Goat anti-rabbit conjugated Alexa-488 antibody (1:200; Invitro-
gen) was used as the secondary antibody. For nuclear staining,
sections were incubated in 0.1 mg/ml 4,6 diamidino-2-phenylin-
dole (DAPI; Invitrogen) for 3 min. Fluorescence was observed
microscopically and fluorescence intensity of immunostaining was
evaluated with ImageJ software (NIH).
Statistical Analysis
All experiments have more than 3 biological repeats and all
values were presented as mean 6 standard deviation. Statistical
comparisons were analyzed with the Student’s t-test and a p-value
less than 0.05 was considered statistically significant.
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